Scarica l'app Stockscreener
1,013.85
2.24%
-19.71
Dopo l'orario di chiusura:
1014.49
0.64
+0.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1,033.56
Aprire:
$1032.625
Volume 24 ore:
3.12M
Relative Volume:
0.84
Capitalizzazione di mercato:
$907.41B
Reddito:
$59.42B
Utile/perdita netta:
$18.41B
Rapporto P/E:
50.14
EPS:
20.2197
Flusso di cassa netto:
$6.44B
1 W Prestazione:
-8.51%
1M Prestazione:
+11.42%
6M Prestazione:
+31.93%
1 anno Prestazione:
+21.76%
Intervallo 1D:
$1,007.18
$1,032.62
Intervallo di 1 settimana:
$1,007.18
$1,099.05
Portata 52W:
$623.78
$1,111.99
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,013.85 | 925.06B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
202.48 | 494.70B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
228.69 | 406.92B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.45 | 256.58B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.89 | 253.84B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Lilly and IU announce $40M partnership to expand clinical trial access - Indianapolis Recorder
IU, Eli Lilly ink partnership for clinical trials - Indiana Public Media
Eli Lilly and Company (LLY): A Bull Case Theory - Finviz
A deal with Donald Trump is boosting this pharma giant - Investors' Chronicle
Eli Lilly (LLY): BMO Capital Raises Price Target, Maintains Rati - GuruFocus
Eli Lilly stock price target raised to $1,200 by BMO on obesity drug outlook - Investing.com Canada
Eli Lilly $1 trln value is bet on Coke-like future - Breakingviews
BMO Capital Adjusts PT on Eli Lilly and Company to $1,200 From $1,100, Maintains Outperform Rating - MarketScreener
FDA approves Eli Lilly’s Jaypirca in relapsed or refractory CLL/SLL - Pharmaceutical Business review -
Eli Lilly, IU agree to $40 million agreement to expand clinical trials - IndyStar
Eli Lilly And Indiana University Sign $40 Mln Agreement To Expand Clinical Trials In Indiana - Nasdaq
Lilly, Indiana University launch new partnership - WTHR
Eli Lilly, Indiana University launch new partnership - WTHR
Eli Lilly’s Jaypirca Granted Traditional FDA Approval In Treating Certain Cancers - Stocktwits
Lilly Announces Changing The Thread Collection Campaign - InkFreeNews.com
Tag Archives: Changing the Thread Collection - InkFreeNews.com
Lilly and IU partner to enhance clinical trials and treatments for Hoosiers - WISH-TV
Lilly, IU Boost Hoosier Access to Trials, Treatments - Mirage News
Lilly and IU to expand access to clinical trials and latest innovative treatments for Hoosiers - News at IU
Lilly, IU sign clinical trial, research agreement worth up to $40M - Inside INdiana Business
Eli Lilly and Company (LLY) Stock: Gains Expanded FDA Approval for Jaypirca - CoinCentral
1 reason to buy Eli Lilly hand over fist before the new year - MSN
Eli Lilly (LLY) Gains FDA Approval for Expanded Use of Jaypirca - GuruFocus
As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock? - Barchart.com
Morgan Stanley Bullish on Eli Lilly and Company (LLY) - MSN
Eli Lilly announces FDA approval of expanded indication for Jaypirca - TipRanks
Lilly’s Jaypirca receives FDA approval for expanded CLL/SLL use By Investing.com - Investing.com Australia
Eli Lilly (LLY) Secures FDA Approval for Pirtobrutinib in Leukem - GuruFocus
1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year - The Motley Fool
High Margins, 3.5% Discount: Buy Eli Lilly Stock Now - Trefis
Insulin Analog Market Forecasting USD 25.29 Billion Valuation by 2034 - GlobeNewswire Inc.
Eli Lilly Stock Now 3.5% Cheaper, Time To Buy - Trefis
Inside Eli Lilly’s Alzheimer’s campaign blitz during holiday season - PRWeek
Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market? - TradingView
Eli Lilly (LLY) Pauses UK Investments Amidst Awaited Drug Approval Changes - GuruFocus
Eli Lilly to delay resuming U.K. investments, FT reports - TipRanks
Eli Lilly not yet ready to unfreeze UK investments, says pharma bossFT - MarketScreener
Lilly builds on BTK inhibitor Jaypirca's 'unique potential impact' with label expansion into earlier lymphoma treatment - Fierce Pharma
Investors have sky-high expectations for Eli Lilly - medwatch.com
Eli Lilly stock price target raised to $1,163 by Guggenheim on GLP-1 growth - Investing.com
Guggenheim Adjusts Price Target on Eli Lilly and Company to $1,163 From $1,036, Maintains Buy Rating - MarketScreener
Bernstein Reaffirms Price Target on Eli Lilly (LLY) After Breakthrough Gains - MSN
Eli Lilly lowers Zepbound costs amid rising calls for affordability - TechTarget
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website - sharewise.com
Transcript : Eli Lilly and Company Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 10 - MarketScreener
Polar Capital Healthcare Trust reveals top holdings, led by Eli Lilly - Investing.com Australia
BMO Capital reiterates Outperform rating on Eli Lilly stock amid price cuts - Investing.com
Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker - ts2.tech
Helping patients fend off illness - Fast Company
Eli Lilly slashes Zepbound prices: Check out the updated costs and where to buy the weight-loss drug - The Times of India
Lilly To Offer Direct-To-Employer Programs - InkFreeNews.com
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lilly Eli Co Azioni (LLY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | 10% Owner |
Nov 25 '25 |
Sale |
1,095.35 |
147,061 |
161,082,640 |
92,212,610 |
| LILLY ENDOWMENT INC | 10% Owner |
Nov 24 '25 |
Sale |
1,068.52 |
142,307 |
152,058,091 |
92,359,671 |
| LILLY ENDOWMENT INC | 10% Owner |
Nov 21 '25 |
Sale |
1,058.66 |
105,326 |
111,504,098 |
92,501,978 |
1.60%
0.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):